Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
AbstractDespite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. View Full-Text
Share & Cite This Article
Hofmann, S.; Schubert, M.-L.; Wang, L.; He, B.; Neuber, B.; Dreger, P.; Müller-Tidow, C.; Schmitt, M. Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). J. Clin. Med. 2019, 8, 200.
Hofmann S, Schubert M-L, Wang L, He B, Neuber B, Dreger P, Müller-Tidow C, Schmitt M. Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). Journal of Clinical Medicine. 2019; 8(2):200.Chicago/Turabian Style
Hofmann, Susanne; Schubert, Maria-Luisa; Wang, Lei; He, Bailin; Neuber, Brigitte; Dreger, Peter; Müller-Tidow, Carsten; Schmitt, Michael. 2019. "Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)." J. Clin. Med. 8, no. 2: 200.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.